| 881 wileyonlinelibrary.com/journal/cas 1 | INTRODUC TI ON Renal cell carcinoma (RCC) is the most common type of histology in kidney cancer and represents the 6th and 10th most frequently diagnosed cancer in men and women, respectively. 1,2 Despite new systemic approaches in RCC treatment including tyrosine kinase inhibitors, 3,4 mTOR inhibitors 5 and immune checkpoint inhibitors, 6 survival still depends on the success of surgical treatment. 7,8 The median overall survival of metastatic RCC treated with a combination of cytoreductive nephrectomy and vascular endothelial growth factor targeted therapy was 19.8 months compared to 9.4 months for patients who were not treated with cytoreductive therapy. 9
TRIM44 overexpression was significantly associated with clinical M stage, histologic type (clear cell) and presence of lymphatic invasion (P = .047, P = .005, and P = .028, respectively). Moreover, TRIM44 overexpression was significantly associated with poor prognosis in terms of cancer-specific survival (P = .019). Gain-of-function and loss-of-function studies using TRIM44 and siTRIM44 transfection showed that TRIM44 promotes cell proliferation and cell migration in two RCC cell lines, Caki1 and 769P. To further investigate the role of TRIM44 in RCC, we performed integrated microarray analysis in Caki1 and 769P cells and explored the data in the Oncomine database. Interestingly, FRK was identified as a promising candidate target gene of TRIM44, which was downregulated in RCC compared with normal renal tissues. We found that cell proliferation was inhibited by TRIM44 knockdown and then recovered by siFRK treatment. Taken together, the present study revealed the association between high expression of TRIM44 and poor prognosis in RCC patients and that TRIM44 promotes cell proliferation by regulating FRK.
K E Y W O R D S
FRK, immunohistochemistry, microarray, renal cell carcinoma, TRIM Discovery of new therapeutic targets is required to improve prognosis in metastatic RCC patients.
Tripartite motif (TRIM) family proteins are a group of proteins possessing unique domains, such as the Really Interesting New Gene (RING) finger, B-box and coiled-coil domain. TRIM proteins are subclassified into C-I to C-XI and one unclassified (UC) subgroup according to their types of structure. 10 TRIM proteins that belong to subgroup C-I to C-XI all have a RING finger domain, which is responsible for E3 ubiquitin activity. 10, 11 Therefore, most of the TRIM proteins are directly involved in ubiquitination, which is a common process in post-translational modification. 11 These proteins are likely to be involved in innate immunity and cancer. 10, 12 TRIM44 is one of the proteins belonging to the UC subgroup and does not possess the RING finger domain. 11 Instead, it contains a zinc-finger ubiquitin binding domain (ZF UBP) that is also found in ubiquitin specific protease (USP) USP7/HAUSP, USP20/VDU2 and USP5/IsoT, which are members of the USP family. [13] [14] [15] [16] USP are involved in the deubiquitination process. [14] [15] [16] The oncogenic effects of TRIM44 have been reported in a number of studies in various types of cancers. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] We have previously shown that TRIM44 is involved in carcinogenesis of testicular germ cell tumor and breast cancer. 21, 22 Other reports have suggested its involvement with various pathways, including mTOR, 23, 24 NFκB 25 and MAPK. 26 However, the mechanism of TRIM44 involvement in carcinogenesis of RCC remains unknown.
In the present study, we aimed to investigate the clinical significance and function of TRIM44 in RCC and to further identify targeted genes of TRIM44.
| MATERIAL S AND ME THODS

| Patient characteristics and tissue preparation
Tissue samples were obtained from 102 patients with renal cell carcinoma who underwent surgical treatment either by partial nephrectomy or radical nephrectomy between 1989 and 2015. No patients received neoadjuvant cancer treatment including immunotherapy and molecular-target therapy. Staging was performed according to the AJCC staging system (https ://www.cancer.org/cance r/kidneycance r/detec tion-diagn osis-stagi ng/stagi ng.html).
The present study was carried out in accordance with the Helsinki declaration, and was approved by our institutional ethical committee (#2283). All patients provided written informed consent.
| Immunostaining and immunohistochemical assessment
A Histofine Kit (Nichirei, Bioscience Tokyo, Japan), which employs the streptavidin-biotin amplification method, was used for immunohistochemistry in our study. As primary antibody, we applied 1:200 diluted rabbit polyclonal antibody. Human breast carcinoma tissue was used as the positive control for TRIM44 immunostaining, 21 while rabbit immunoglobulin G (IgG) was used as the negative control.
Immunoreactivity (IR) of TRIM44 was evaluated by intensity score of immunostaining, which was rated from 0 to 2+ (0: none, 1+: weak, 2+: moderate to strong) based on a report by Yamada et al 22 with a modification. Positive IR was defined as having intensity score ≥1+. ST (pathologist who was blind to the clinical data) evaluated the slides.
| Antibodies
Anti-TRIM44 polyclonal antibody was raised in our laboratory as described in a previous report. 22 Briefly, this antibody is an affinity purified rabbit polyclonal antibody raised by immunizing rabbits with a glutathione S-transferase (GST) fusion protein with amino acids of full-length mouse TRIM44 protein as an antigen. GST-bound resin was used to remove anti-GST antibody. The cross-reactivity to human TRIM44 protein and quality of anti-TRIM44 antibody were confirmed by western blotting analysis in previous literature. 22 
| Plasmid construction and transfection
| Cell culture
We used human RCC-originated cells (Caki-1 and 769P). These cells were cultured at 37°C in a humidified air and 5% CO 2 atmosphere.
DMEM and RPMI with 10% FBS and 1% penicillin-streptomycin were used for media to cultivate Caki1 and 769P cells, respectively (Sigma-Aldrich Japan).
| Western blot analysis
Cell lysis, gel electrophoresis and western blot analysis were performed as previously described. 22 Cells were lysed with NP40 buffer (50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 1% NP-40) containing proteinase inhibitor. SDS sample buffer was added to these cell lysates and used for gel electrophoresis. Anti-TRIM44 and anti-β-actin from Sigma were used for primary antibodies. An enhanced chemiluminescence system (GE Healthcare UK) was used for western blot analysis.
| RNA extraction and quantitative reverse transcription-polymerase chain reaction
Quantitative RT-PCR (qRT-PCR) was performed as previously described. 27 Total RNA extraction from cell lines was performed using ISOGEN reagent (Nippon Gene, Tokyo, Japan). First-strand cDNA was synthesized using PrimeScript (Takara). The Applied Biosystems 7300
Real-Time PCR System and SYBR Green fluorescence were used for qRT-PCR. The following primers were designed and used for qRT-PCR:
FRK reverse: 5′-TTCGCCAAACTGACCAGATCC-3′. Assays were performed in quintuplicate, and data are presented as mean value ± SD.
| Small interfering RNA transfection
| Cell migration assay
Cell migration assay was carried out as previously described. 22 Cell culture inserts with an 8. 
| RE SULTS
| TRIM44 is overexpressed in renal cell carcinoma and is associated with poor prognosis
Analysis of the ONCOMINE datasets (https ://www.oncom ine.org) showed that mRNA expression of TRIM44 was higher in kidney cancer than in normal kidney tissue ( Figure 1A,B ).
Immunohistochemistry of TRIM44 protein in RCC revealed that TRIM44 immunoreactivity (IR) was detected in the cytoplasm of RCC cells ( Figure 1C,D) . We found that overexpression of TRIM44 was significantly associated with clinical M stage, histologic type (clear cell type) and presence of lymphatic invasion (P = .047, P = .005 and P = .028, respectively; Tables 1 and 2 ). Multivariate analysis also revealed that TRIM44 overexpression was a significant risk factor of cancer-specific mortality in patients with RCC (Table 3) . Kaplan-Meier curves showed that cancer-specific survival was significantly shorter in patients with TRIM44 overexpression ( Figure 1H ). 
TA B L E 1
| TRIM44 overexpression promoted proliferation and migration and vice versa in TRIM44 knockdown in renal cell carcinoma cells
Overexpression of TRIM44 in Caki1 and 769P cells was confirmed by qRT-PCR and western blot analysis (Figure 2A ,B and Figure   S1A ,B). Cell proliferation and migration were markedly promoted in RCC cells treated with TRIM44 overexpression ( Figures 2C-E and S1C-E).
Loss-of-function studies in RCC cell lines were performed using two types of siTRIM44. Caki1 and 769P cells were treated with siTRIM44-A and siTRIM4-B. TRIM44 knockdown in these siTRIM44-treated RCC cells were confirmed by qRT-PCR and western blotting ( Figures 2F,G and S1F,G). Cell proliferation and migration were significantly repressed by TRIM44 knockdown (Figures 2H-J and S1H-J).
| FRK was identified as the target gene of TRIM44 in renal cell carcinoma
We conducted a microarray analysis to investigate TRIM44regulated signals that were responsible for RCC progression by identifying differentially expressed genes in RCC cell lines treated with either TRIM44 knockdown or overexpression.
Integrated analysis containing microarray data of 769P and Caki1 cells revealed 12 candidate genes that were potentially downregulated by TRIM44 ( Figure 3A , Table S1 ). Of the 12 genes that were downregulated by TRIM44, three genes were found to possess tumor suppressive functions ( Figure 3A; FRK, EGR1 and BCL2L14) . [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] We then used the Oncomine dataset to analyze the expression level of these three genes in tumors. FRK was the only gene that showed low We also explored upregulated genes by TRIM44 using the same microarray data ( Figure S3 , Table S2 ). Fourteen candidate genes were identified by integrating four sets of microarray data ( Figure   S3 ). Of these 14 genes, GRK5 was the only gene known to possess oncogenic effect ( Figure S3 ). In fact, the oncogenic effect of GRK5 in renal cell carcinoma was previously reported. 43 
| TRIM44 promotes cell proliferation by regulating FRK in renal cell carcinoma
Knockdown of FRK in Caki1 cells was confirmed by qRT-PCR ( Figure 4A ). Double knockdown of TRIM44 and FRK was also performed in Caki1 cells by using siTRIM44 + siFRK and was confirmed by qRT-PCR ( Figure 4B ,C). MTS assay of Caki1 cells treated with siCTRL, siFRK, siTRIM44 + siCTRL or siTRIM44 + siFRK revealed that cell proliferation was inhibited by TRIM44 knockdown and then promoted by siFRK supplement (Figure 4D,E) . Note: Pearson's χ 2 tests were used for statistical analysis.
Double induction of TRIM44 and FRK in Caki1 cells was car
Abbreviations: IR, immunoreactivity; TRIM44, tripartite motif 44. "IR positive" was defined as intensity score ≥1. a Fisher's test was used when categorical values were under 5.
analysis ( Figure 4F ). Overexpression of TRIM44 was also confirmed in Caki1 cells transfected with TRIM44 alone or both TRIM44 and
Halo-FRK ( Figure 4F ). Then, MTS assay was performed in Caki1 cells treated with Vector, Vector + TRIM44 and TRIM44 + Halo-FRK ( Figure 4G) . We observed increased cell proliferation through TRIM44 overexpression that was then attenuated by overexpressing Halo-FRK with TRIM44 ( Figure 4G ).
| Proposed mechanism of TRIM44 involvement in renal cell carcinoma carcinogenesis
The present study revealed that TRIM44 promotes cell proliferation and migration in RCC cells. Furthermore, TRIM44 may promote cell proliferation of RCC cells by inhibiting FRK ( Figure 4H ). 
| D ISCUSS I ON
TRIM44 is genetically located at chromosome 11p13 and belongs to the UC subgroup of the TRIM family, which do not possess the RING finger domain. 10, 11 Therefore, TRIM44 itself may not have the E3 ligase activity. From the molecular structural perspective, this suggests a couple of hypotheses of how TRIM44 is involved in the ubiquitination process. One theory is that TRIM44 may function as a promoter of deubiquitination. The N-terminal region of TRIM44 contains the ZF UBP that binds to ubiquitin with high affinity. 14 ZF UBP are found in the deubiquitinating enzymes containing USP. 13 USP typically remove ubiquitin from substrates, leading to the inhibition of substrate degradation. 15, 16 For example, USP7/HAUSP deubiquitinates and stabilizes p53(Li M). 15 USP20/VDU2 deubiquitinates and stabilizes HIF1α. 16 Previously, we reported that TRIM44 binds to TRIM17 and stabilizes it to activate the function of TRIM17. 13 TRIM44 also targets virus-induced signaling adaptor (VISA) and stabilizes it by preventing VISA ubiquitination. 44 Another theory can be projected by reflecting on mechanisms of other TRIM proteins. TRIM29 is one of the proteins that also do not possess the RING finger. 11 This protein is suggested to be involved in DNA repair response by serving as a scaffold protein to assemble DNA repair proteins into damaged chromatin. 45 Xing et al 46 show that the E3 ligase activity, which is usually the distinct function of the RING finger domain, could be functionally compensated by B-box2 domain. Therefore, the B-box2 of TRIM44 could have a similar function that may directly affect the ubiquitination process. In theory, TRIM44 is capable of targeting proteins directly or indirectly for degradation by ubiquitination despite the structural absence of RING finger domain.
Accumulating studies have shown that TRIM family proteins may positively or negatively regulate carcinogenesis depending on the types of TRIM or the origin of cancer. 10, 11 Specifically, TRIM44 has been reported in a number of studies showing oncogenic effect in various cancers. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Ong et al 20 have reported that TRIM44 overexpression resulted from genomic amplification in 16.1% of all epithelial cancers. From a clinicopathological point of view, we previously showed that TRIM44 overexpression was associated with poor prognosis in testicular germ cell tumors. 22 Other studies include an immunohistochemical (IHC) analysis that demonstrated that overexpression of TRIM44 was an independent predictor of poor prognosis in a series of 109 patients with epithelial ovarian cancer. 47 Another IHC study revealed that TRIM44 overexpression was significantly associated with histological grade, depth of myometrial invasion and lymph node metastasis in endometrial carcinoma. 48 In esophageal squamous cell carcinoma, overexpression of TRIM44 was associated with the status of lymph node metastasis and poor overall survival. 49 As described, the role of TRIM44 in cancer is likely to be oncogenic, although the involved mechanism seems to differ depending on types of cancer. TRIM44 facilitated the cell growth and motility of non-small cell lung cancer cells through the mTOR signaling F I G U R E 3 Integrative analysis of microarray data was performed to identify genes downregulated by TRIM44 in renal cell carcinoma (RCC) cells. A, Microarray analysis was performed to identify TRIM44regulated genes. For 769P cells, expression levels were analyzed in TRIM44 knockdown cells (siTRIM44-A vs siCTRL and siTRIM44-B vs siCTRL). Expression levels were also analyzed in TRIM44 knockdown and TRIM44 overexpression Caki1 cells (siTRIM44-A vs siCTRL and TRIM44 overexpression vs Vector). To analyze genes showing tumor suppressive effect, upregulated genes by TRIM44 knockdown or downregulated genes by overexpression were identified in each microarray dataset, as shown in the flowchart. These data were integrated to identify the overlapped TRIM44-regulated genes that possess a tumor suppressive effect (three genes). B, C, Oncomine data showing expression level of FRK in RCC samples. Expression levels of FRK showed low levels in cancer compared with benign renal tissues. D-G, mRNA expression levels of FRK normalized by GAPDH are shown (*P < .05, **P < .01, ***P < .001; Student's t test)
pathway. 24 In non-small cell lung cancer cells and breast cancers, cholangiocarcinoma has indicated that TRIM44 overexpression activated MAPK signaling and reversed cell EMT and apoptosis. 26 Despite the known TRIM44-regulated pathways mentioned, these pathways were not enriched in the RCC cells according to the microarray results in the present study. In contrast, the present study identified FRK, a novel tumor suppressive gene, 40, 50 as a direct or indirect target of TRIM44.
The fyn-related kinase (FRK) is one of the tumor suppressive genes that belong to a subfamily of non-receptor tyrosine kinases. 40, 50 FRK positively regulated PTEN by phosphorylating PTEN at tyrosine residue 336, which led to a stabilization of PTEN protein in breast cancer cells. 50 This mutation of the tyrosine residue seemed to prevent the NEDD4-1 mediated ubiquitination of PTEN. 50 Another study revealed that FRK inhibited cell migration of breast cancer cells through suppressing EMT. 39 FRK is also involved in large cell lymphoma and glioma as a tumor suppressor. 38, [40] [41] [42] FRK overexpression caused G1 phase arrest that led to apoptosis in glioma cells. 41 In the present study, TRIM44 downregulated FRK which showed a tumor suppressive effect in RCC cells. However, the specific regulatory mechanism of FRK by TRIM44 remains unclear, because our results cannot distinguish whether TRIM44 suppresses FRK directly or indirectly. It is possible that TRIM44 may indirectly suppress FRK through regulating other transcriptional factors.
In conclusion, our study shows that overexpression of TRIM44 is associated with poor prognosis in patients with RCC and that TRIM44 targets FRK and promotes cell proliferation and migration.
